What’s Separating The Growers And No-Growers In China?
Multinational pharma firms have had a widely varied quarter in China, with some clear winners emerging with double-digit growth while others are still in the doldrums. What are the factors behind the figures?
You may also be interested in...
Fallout can be an opportunity when both makers and service providers see the need to collaborate to solve China's acute and changing regulatory demand.
China continues to be the brightest star in AstraZeneca's emerging markets firmament amid some "softness" in other countries, and the UK group sees attractive prospects in the country for some of its innovative branded products.
The second quarter has been a period of stabilization for multinational drug makers in China, where the challenges of cost-cutting and a national policy to encourage domestic generics remain. Big pharmas including Novartis and Roche are voluntarily reduce prices for major products, to help them compete, reflecting a new willingness to improve patient access in the world's second-largest pharma market.